Whitney Ijem
Stock Analyst at Canaccord Genuity
(4.51)
# 344
Out of 5,180 analysts
127
Total ratings
50%
Success rate
37.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GUTS Fractyl Health | Maintains: Buy | $8 | $0.46 | +1,647.49% | 3 | Mar 26, 2026 | |
| OCGN Ocugen | Initiates: Buy | $12 | $1.81 | +562.98% | 1 | Mar 17, 2026 | |
| WVE Wave Life Sciences | Maintains: Buy | $43 → $52 | $7.25 | +617.24% | 4 | Mar 10, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Buy | $66 → $21 | $7.72 | +172.02% | 7 | Mar 5, 2026 | |
| PASG Passage Bio | Maintains: Buy | $67 → $23 | $7.85 | +192.99% | 8 | Mar 4, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $54 → $48 | $12.82 | +274.41% | 7 | Mar 3, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $141 → $140 | $86.97 | +60.98% | 11 | Mar 2, 2026 | |
| NGNE Neurogene | Initiates: Buy | $200 | $20.16 | +892.06% | 1 | Feb 27, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $98 → $104 | $56.49 | +84.10% | 10 | Feb 26, 2026 | |
| BEAM Beam Therapeutics | Initiates: Buy | $74 | $23.83 | +210.53% | 1 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $79 | $20.95 | +277.09% | 10 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $411 → $441 | $446.54 | -1.24% | 10 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $415 → $429 | $330.87 | +29.66% | 10 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $0.69 | +622.13% | 7 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $204 | $124.65 | +63.66% | 8 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $14 | $4.47 | +213.20% | 11 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $10 | $3.58 | +179.33% | 9 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $150 | $21.76 | +589.34% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $139.37 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $120 → $240 | $5.57 | +4,208.80% | 4 | Jul 23, 2019 |
Fractyl Health
Mar 26, 2026
Maintains: Buy
Price Target: $8
Current: $0.46
Upside: +1,647.49%
Ocugen
Mar 17, 2026
Initiates: Buy
Price Target: $12
Current: $1.81
Upside: +562.98%
Wave Life Sciences
Mar 10, 2026
Maintains: Buy
Price Target: $43 → $52
Current: $7.25
Upside: +617.24%
Arcturus Therapeutics Holdings
Mar 5, 2026
Maintains: Buy
Price Target: $66 → $21
Current: $7.72
Upside: +172.02%
Passage Bio
Mar 4, 2026
Maintains: Buy
Price Target: $67 → $23
Current: $7.85
Upside: +192.99%
Intellia Therapeutics
Mar 3, 2026
Maintains: Buy
Price Target: $54 → $48
Current: $12.82
Upside: +274.41%
Rhythm Pharmaceuticals
Mar 2, 2026
Maintains: Buy
Price Target: $141 → $140
Current: $86.97
Upside: +60.98%
Neurogene
Feb 27, 2026
Initiates: Buy
Price Target: $200
Current: $20.16
Upside: +892.06%
BioMarin Pharmaceutical
Feb 26, 2026
Maintains: Buy
Price Target: $98 → $104
Current: $56.49
Upside: +84.10%
Beam Therapeutics
Feb 20, 2026
Initiates: Buy
Price Target: $74
Current: $23.83
Upside: +210.53%
Feb 18, 2026
Maintains: Buy
Price Target: $128 → $79
Current: $20.95
Upside: +277.09%
Feb 17, 2026
Maintains: Hold
Price Target: $411 → $441
Current: $446.54
Upside: -1.24%
Feb 17, 2026
Maintains: Buy
Price Target: $415 → $429
Current: $330.87
Upside: +29.66%
Dec 18, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $0.69
Upside: +622.13%
Dec 16, 2025
Maintains: Buy
Price Target: $148 → $204
Current: $124.65
Upside: +63.66%
Aug 13, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $4.47
Upside: +213.20%
Jul 25, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $3.58
Upside: +179.33%
Nov 7, 2024
Maintains: Buy
Price Target: $148 → $150
Current: $21.76
Upside: +589.34%
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $139.37
Upside: -
Jul 23, 2019
Upgrades: Overweight
Price Target: $120 → $240
Current: $5.57
Upside: +4,208.80%